Financial Performance - Total revenue for the first quarter of fiscal 2025 was $14.1 million, an increase of 12% compared to $12.6 million in the same period last year[3] - Adjusted EBITDA for the first quarter was $2.0 million, a significant improvement from an adjusted EBITDA loss of $1.7 million in the first quarter of fiscal 2024[4] - Net income for the first quarter was $1.3 million, compared to a net loss of $2.6 million in the same period last year[4] - Total costs and operating expenses for the first quarter were $12.7 million, a decrease of $2.4 million or 15.8% from $15.1 million in the first quarter of fiscal 2024[3] - Total margin improved to 49.7% for the first quarter, up from 38.8% in the same period last year[5] Cost Management - Cost of oncology services decreased by $612,000, or 8.0%, to $7.1 million compared to $7.7 million for the same period last year[5] - Research and development expenses decreased by $1.3 million, or 47.9%, to $1.5 million compared to $2.8 million for the same period last year[6] - The company plans to continue focusing on cost reductions to maintain profitability despite potential revenue and margin volatility in upcoming quarters[2] - Stock-based compensation expense decreased to $258 from $423 year-over-year[16] Cash Flow and Liquidity - The company ended the quarter with cash on hand of approximately $2.9 million and has no debt[7] - Net cash provided by operating activities was $311, a significant improvement from a cash used of $3,991 in the prior year[16] - Cash at the end of the period was $2,892, down from $4,869 at the end of the same period last year[16] - Net cash used in investing activities was $668, with no purchases of property and equipment reported for the current period[16] - Net cash used in financing activities was $37, compared to $590 in the previous year[16] - The company reported a net increase in cash of $274, contrasting with a decrease of $5,249 in the same period last year[16] - Changes in operating assets and liabilities resulted in a cash outflow of $1,927, an improvement from $2,725 in the previous year[16] Future Outlook - The company is cautiously optimistic about future growth, citing operational improvements and a strong team as key factors[2] Depreciation and Allowance - Depreciation and amortization expense remained relatively stable at $449, compared to $445 in the prior year[16] - Allowance for doubtful accounts and estimated credit losses showed a reversal of $71, compared to an expense of $162 in the previous year[16]
Champions Oncology(CSBR) - 2025 Q1 - Quarterly Results